新兴RNA疗法降低脂蛋白(a)水平:JACC焦点研讨会2/4
脂蛋白(a)[Lp(a)]已被公认为心血管疾病风险因素,但因果关系尚待随机试验验证。抑制肝细胞载脂蛋白(a)生成的RNA疗法可有效降低血浆Lp(a)水平。2期试验显示反义寡核苷酸pelacarsen使平均Lp(a)降低80%,98%受试者达到治疗中Lp(a)<125 nmol/l(约50 mg/dl)。3期Lp(a)HORIZON结局试验正在入组约7,680例有心肌梗死、缺血性卒中或症状性外周动脉疾病且LDL-C受控的患者,比较pelacarsen与安慰剂。
要点
- Pelacarsen在2期试验中降低Lp(a)达80%,98%受试者Lp(a)<125 nmol/l。
- 3期Lp(a)HORIZON试验评估pelacarsen对主要心血管事件的影响。
- 其他RNA靶向降Lp(a)疗法处于临床前或临床研发阶段。
核心结论
- 抑制载脂蛋白(a)生成的RNA疗法可显著降低Lp(a)水平,但需3期试验验证能否减少心血管事件。
研究设计与样本
- JACC焦点研讨会综述,汇总RNA疗法降低Lp(a)的2期临床试验及正在进行的3期结局试验设计。
主要发现
- 2期试验中pelacarsen降低平均Lp(a)80%,98%受试者达到治疗中Lp(a)<125 nmol/l(约50 mg/dl)。
- 3期Lp(a)HORIZON试验计划入组约7,680例有心肌梗死、缺血性卒中或症状性外周动脉疾病且LDL-C受控的患者。
关键数值与推荐
- Lp(a)HORIZON主要终点为Lp(a)>70 mg/dl和>90 mg/dl亚组的主要不良心血管事件,任一阳性即试验成功。
临床怎么用
- 目前RNA疗法降低Lp(a)仍处于研究阶段,临床实践需等待3期结局试验结果。
局限性
- Lp(a)降低能否减少心血管事件尚未经随机试验证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lipoprotein(a) [Lp(a)] has risen to the level of an accepted cardiovascular disease risk factor, but final proof of causality awaits a randomized trial of Lp(a) lowering. Inhibiting apolipoprotein(a) production in the hepatocyte with ribonucleic acid therapeutics has emerged as an elegant and effective solution to reduce plasma Lp(a) levels. Phase 2 clinical trials have shown that the antisense oligonucleotide pelacarsen reduced mean Lp(a) levels by 80%, allowing 98% of subjects to reach on-treatment levels of <125 nmol/l (∼50 mg/dl). The phase 3 Lp(a)HORIZON (Assessing the Impact of Lipoprotein(a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD) outcomes trial is currently enrolling approximately 7,680 patients with history of myocardial infarction, ischemic stroke, and symptomatic peripheral arterial disease and controlled low-density lipoprotein cholesterol to pelacarsen versus placebo. The co-primary endpoints are major adverse cardiovascular events in subjects with Lp(a) >70 mg/dl and >90 mg/dl, in which either of the two being positive will lead to a successful trial. Additional ribonucleic acid-targeted therapies to lower Lp(a) are in preclinical and clinical development. The testing of the Lp(a) hypothesis will provide proof whether Lp(a)-mediated risk can be abolished by potent Lp(a) lowering.
引用
- Tsimikas S, Moriarty PM, Stroes ES, et al. Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4. J Am Coll Cardiol. 2021. PMID: 33766265. doi:10.1016/j.jacc.2021.01.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。